Fondaparinux upregulates thrombomodulin and the endothelial protein C receptor during early-stage reperfusion in a rat model of myocardial infarction.
Fiche publication
Date publication
mai 2016
Journal
Thrombosis research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe
Tous les auteurs :
Guillou S, Tamareille S, Giraud S, Poitevin G, Prunier-Mirebeau D, Nguyen P, Prunier F, Macchi L
Lien Pubmed
Résumé
Fondaparinux (FDX) was demonstrated to be cardioprotective in a rat model of myocardial ischemia reperfusion. In this model, FDX reduced infarct size after 2h of reperfusion, involving the activation of the survivor activating factor enhancement (SAFE) pathway as early as 30min post-reperfusion. Our aim was to study if this cardioprotection could be explained by anti-inflammatory mechanisms and a protective effect on vessels.
Référence
Thromb. Res.. 2016 May;141:98-103